Sickle cell disease nephropathy: an update on risk factors and potential biomarkers in pediatric patients

• Published in: Biomarkers in medicine Vol. 13; no. 11; pp. 965 - 985
• Main Authors: Belisário, André R, da Silva, Ariadna As, Silva, Cristiane Vm, de Souza, Larissa Mg, Wakabayashi, Eduarda A, Araújo, Stanley de A, Simoes-E-Silva, Ana C
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.08.2019
• Subjects: biomarkers; chronic kidney disease; hyperfiltration; microalbuminuria; proteinuria; risk factor; sickle cell anemia; sickle cell disease; sickle cell nephropathy; chronic kidney disease; microalbuminuria; sickle cell nephropathy; biomarkers; proteinuria; risk factor; hyperfiltration; sickle cell anemia; sickle cell disease
• ISSN: 1752-0363; 1752-0371
• DOI: 10.2217/bmm-2019-0105

One of the major chronic complications of sickle cell disease (SCD) is sickle cell nephropathy. The aim of this review is to discuss the pathophysiology, natural history, clinical manifestations, risk factors, biomarkers and therapeutic approaches for sickle cell nephropathy, focusing on studies with pediatric patients. The earliest manifestation of renal disease is an increase in the glomerular filtration rate. A finding that may also be observed in early childhood is microalbuminuria. Nephrin, KIM-1, VGFs, chemokines and renin-angiotensin system molecules have emerged as potential early markers of renal dysfunction in SCD. In regards to a therapeutic approach, renin-angiotensin system inhibitors and angiotensin receptor blockers seem to be effective for the control of albuminuria in adults with SCD, although new studies in children are needed. The precise moment to begin renoprotection in SCD patients who should be treated remains to be determined.